Fourth
GAVI Board Meeting, Noordwijk, The Netherlands, 19 November 2000
Task Force on Research and Development: terms of
reference and composition
Dr Peter Wilson, consultant to the Task Force on
Research and Development (R&D), presented a summary
(Word 438k) of the composition, objectives, strategies and
goals of the task force.
The Board:
3.1 Approved the composition
of the R&D Task Force which assures a range of expertise in
vaccinology and immunology, provided that the recommendation in
para. 3.4 below is addressed. The task force comprises:
- three co-chairs from WHO, industry
and academia, and
- five members from different geographical regions.
3.2 Endorsed the advisory
role that the task force will play in the process of identifying
and supporting the GAVI research and development agenda. The task
force will:
- identify highest priority research gaps and make
recommendations to the GAVI Board;
- provide technical support to implementing partners
in:
- identifying key barriers and strategies to address research
and development gaps;
- evaluating alternative project structures; and
- setting up a research and development agenda and timetable;
- monitor adherence to an agreed-upon agenda and
timetable.
3.3 Approved the recommendation
of the task force that GAVI should focus initially on three vaccine
products: pneumococcal, rotavirus and meningococcal A (or A/C).
These products, described in the presentation
(Powerpoint 113k), were picked from a larger list because
they satisfied all or most of the following criteria:
- either there is no currently-registered
vaccine, or the existing vaccine has drawbacks which severely
limit its utility;
- the vaccine has a high potential impact; and could
significantly reduce morbidity and mortality in children and/or
adults;
- a high probability of success in short/medium
term use of the vaccine;
- the vaccine has a potential for improving immunization
systems;
- the vaccine fills a strategic gap, i.e., no other
effort is currently focusing on it;
- there is a lack of other, non-vaccine solutions
(preventative or curative).
3.4 Endorsed the proposal
outlined in the presentation that the task force, in consultation
with the GAVI Working Group and others in the research community,
would seek to identify up to three promising fields of research
on new technologies and systems for improving immunization services.
Similar criteria as those used for vaccine product
selection would be used to identify the under-addressed research
fields, which may include:
- proven strategies for reaching the hard-to-reach,
including the application of lessons learned from polio eradication;
- improved information technology (IT) infrastructures
for better management of immunization services;
- development of new technologies including
low-tech devices for increasing immunization
and injection safety, reducing the need for a cold chain, and/or
other tools that could improve efficiency.
3.5 Recognized that
the current composition of the task force does not include experts
in the area of applied and operational research, and encouraged
the task force to add two to four appropriately qualified individuals
to support this research area.
3.6 Requested the task
force to provide the Board with its recommendations on candidate
projects to support immunization services, at the latest by the
Boards next meeting in June 2001.
|